Avisa Diagnostics (FOGCF)
OTHER OTC:FOGCF
US Market

Avisa Diagnostics (FOGCF) Income Statement

14 Followers

Avisa Diagnostics Income Statement

Last quarter (Q ), Avisa Diagnostics's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q, Avisa Diagnostics's net income was $-4.53M. See Avisa Diagnostics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 20Dec 19Dec 18Dec 17Dec 16
Total Revenue
-$ 277.83K$ 838.86K$ 194.34K$ 0.00$ 0.00
Cost of Revenue
$ 1.37K$ 148.55K$ 407.05K$ 93.48K$ 0.00-
Gross Profit
$ -1.37K$ 129.28K$ 431.81K$ 100.86K$ 0.00-
Operating Expense
$ 5.02M$ 828.44K$ 3.08M$ 6.09M$ 74.27K$ 88.37K
Operating Income
$ -5.03M$ -699.16K$ -2.65M$ -5.99M$ -74.27K$ -88.37K
Net Non Operating Interest Income Expense
$ 442.21K$ 16.60K$ -2.00K$ 6.51K$ 0.00-
Other Income Expense
$ 1.93M-$ -1.49M$ -516.51K$ -18.57K$ 304.00
Pretax Income
$ -3.57M$ -715.76K$ -4.13M$ -6.50M$ -74.27K$ -88.07K
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -3.57M$ -715.76K$ -4.13M$ -6.50M$ -74.27K$ -88.07K
Basic EPS
$ 7.44$ -2.10$ -13.50$ -1.50$ -0.02$ -1.30
Diluted EPS
$ 7.44$ -2.10$ -13.50$ -1.50$ -0.02$ -1.30
Basic Average Shares
$ 38.63M$ 348.29K$ 328.06K$ 4.16M$ 3.60M$ 70.60K
Diluted Average Shares
$ 38.63M$ 348.29K$ 328.06K$ 4.16M$ 3.60M$ 70.60K
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
$ -120.00--$ 42.43K$ 36.00K-
Total Expenses
$ -4.61M$ -976.99K$ -3.49M$ 6.18M$ 74.27K$ 88.37K
Net Income From Continuing And Discontinued Operation
$ -3.57M$ -715.76K$ -4.13M$ -6.50M$ -74.27K$ -88.07K
Normalized Income
$ -2.70M$ -526.09K$ -1.55M$ -5.98M$ -74.27K$ -88.37K
Interest Expense
------
EBIT
$ -3.09M$ -698.67K$ -4.13M$ -5.99M$ -74.27K$ -88.37K
EBITDA
$ -3.08M$ -678.64K$ -3.17M$ -4.78M$ -74.27K$ -88.37K
Currency in USD

Avisa Diagnostics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis